Lack of population diversity in commonly used human embryonic stem-cell lines.
University of Michigan, Ann Arbor, MI, Masaryk University, Brno, Czech Republic, Valencia University, Valencia, Spain, University of Michigan, Ann Arbor, MI, .New England Journal of Medicine (Impact Factor: 54.42). 12/2009; 362(2):183-5. DOI: 10.1056/NEJMc0910371
Article: Point/CounterpointJournal of Policy Analysis and Management 06/2012; 31(3). · 0.93 Impact Factor
- [Show abstract] [Hide abstract]
ABSTRACT: Human stem cell research represents an exceptional opportunity for regenerative medicine and the surgical reconstruction of the craniomaxillofacial complex. The correct architecture and function of the vastly diverse tissues of this important anatomical region are critical for life supportive processes, the delivery of senses, social interaction and aesthetics. Craniomaxillofacial tissue loss is commonly associated with inflammatory responses of the surrounding tissue, significant scarring, disfigurement and psychological sequelae as an inevitable consequence. The in vitro production of fully functional cells for skin, muscle, cartilage, bone and neurovascular tissue formation from human stem cells, may one day provide novel materials for the reconstructive surgeon operating on patients with both hard and soft tissue deficit due to cancer, congenital disease or trauma. However the clinical translation of human stem cell technology, including the application of human pluripotent stem cells (hPSCs) in novel regenerative therapies, faces several hurdles which must be solved in order to permit safe and effective use in patients. The basic biology of hPSCs remains to be fully elucidated and concerns of tumourigenicity need to be addressed, prior to the development of cell transplantation treatments. Furthermore, functional comparison of in vitro generated tissue to their in vivo counterparts will be necessary for confirmation of maturity and suitability for application in reconstructive surgery. Here we provide an overview of human stem cells in disease modelling, drug screening and therapeutics, whilst also discussing the application of regenerative medicine for craniomaxillofacial tissue deficit and surgical reconstruction.Stem cells and development 02/2014; · 4.15 Impact Factor
- Biotechnology & Biotechnological Equipment 01/2010; 24(3):1921-1927. · 0.38 Impact Factor
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.